Kuona Patience, Kandawasvika Gwendoline Q, Chunda-Liyoka Catherine, Ruredzo Ian M, Sambo Pauline M, Gorejena-Chidawanyika Pamela, Mantina Hamakwa M, Mtisi Takudzwa J, Phiri Cynthia, Chikara Lawson, Kaweme Natasha M, Chivige Exavior, Namushi Jombo, Maboreke Tendai C, Athale Uma, Masimirembwa Collen
Department of Child, Adolescent and Women's Health, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
SHAZ Program, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Front Med (Lausanne). 2025 May 2;12:1484763. doi: 10.3389/fmed.2025.1484763. eCollection 2025.
Majority of the 500,000 children born with sickle cell disease (SCD) annually are born in Africa. SCD contributes significantly to morbidity and mortality. This is worsened by the reduced access to therapeutic plus preventive care and limited health outcomes data. To address these challenges, we aim to develop and manage a standardized electronic SCD registry, establish consistent standards of care (SoC) for patients, improve the SCD research and biobanking capacity in Zimbabwe and Zambia. This five-year program employs a multi-pronged approach that include infrastructure and skilled manpower capacity building of SCD clinics, registry, biobanking, cohort and implementation science research studies to improve SCD treatment outcomes. We are collaborating with the SickleInAfrica consortium (Ghana, Mali, Nigeria, Tanzania, Uganda, and South Africa), the African Institute of Biomedical Sciences and Technology (AiBST) and St Jude's Children Research Hospital. We have established the SCD registry in Zimbabwe and Zambia for children and adult patients enrolling 1796 (45%) of the targeted 4,000 participants as of March 2024. We are participating in SickleInAfrica consortium research activities, training health workers and educating SCD patient communities on SoC. This collaboration with African researchers, policymakers, health workers, and SCD patient communities will improve uptake of SCD SoC and increase our research capacity.
每年出生的50万名镰状细胞病(SCD)患儿中,大多数出生在非洲。SCD是导致发病和死亡的重要因素。获得治疗和预防护理的机会减少以及健康结果数据有限,使情况更加恶化。为应对这些挑战,我们旨在开发和管理一个标准化的电子SCD登记系统,为患者建立一致的护理标准(SoC),提高津巴布韦和赞比亚的SCD研究及生物样本库能力。这个为期五年的项目采用多管齐下的方法,包括对SCD诊所、登记系统、生物样本库、队列研究和实施科学研究进行基础设施建设和培养技术熟练的人力,以改善SCD的治疗效果。我们正在与非洲镰状细胞病联盟(加纳、马里、尼日利亚、坦桑尼亚、乌干达和南非)、非洲生物医学科学与技术研究所(AiBST)以及圣裘德儿童研究医院合作。截至2024年3月,我们已在津巴布韦和赞比亚为儿童和成年患者建立了SCD登记系统,登记了目标4000名参与者中的1796名(45%)。我们正在参与非洲镰状细胞病联盟的研究活动,培训卫生工作者,并就护理标准对SCD患者群体进行教育。与非洲研究人员、政策制定者、卫生工作者和SCD患者群体的这种合作将提高SCD护理标准的采用率,并增强我们的研究能力。